Potential best-in-class lead program targets Nav1.8, a validated human target for painTHOUSAND OAKS, Calif., Feb. 14, 2024 /PRNewswire/ -- Latigo Biotherapeutics Inc. ('Latigo'), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced its emergence from stealth with a $135 million Series A financing.

2024年2月14日，加利福尼亚州painTHOUSAND OAKS的一个经过验证的人类目标Nav1.8，成为潜在的同类最佳领先计划的目标/PRNewswire/--Latigo Biotherapeutics Inc.（“Latigo”），一家临床阶段的生物技术公司，开发出同类最佳的非阿片类止痛药，从源头上治疗疼痛，今天宣布其从隐形中崛起，获得了1.35亿美元的a系列融资。

Westlake Village BioPartners ('Westlake') incubated the company. Westlake led the Series A financing with 5AM Ventures and Foresite Capital as co-leads with participation from Corner Ventures..

Westlake Village BioPartners（“西湖”）孵化了该公司。Westlake与5AM Ventures和Foresite Capital共同领导了A系列融资，Corner Ventures参与了融资。。

Continue Reading

继续阅读

Desmond Padhi, PharmD, Latigo Biotherapeutics interim CEO

Desmond Padhi，医学博士，Latigo Biotherapeutics临时首席执行官

Nancy Stagliano, PhD, chair of Latigo board of directors

Latigo董事会主席Nancy Stagliano博士

The company has appointed Desmond Padhi, Pharm.D., operating partner at Westlake as interim chief executive officer (CEO) and Nancy Stagliano, Ph.D., CEO of Neuron23, Inc., as chair of the board. Proceeds from the financing will support the continued advancement of Latigo's portfolio of novel pain therapeutics and the growth of the company and its platform..

该公司已任命Westlake运营合伙人Desmond Padhi博士为临时首席执行官（CEO），Neuron23，Inc.首席执行官Nancy Stagliano博士为董事会主席。融资收益将支持Latigo新型疼痛疗法投资组合的持续发展以及公司及其平台的发展。。

The Thousand Oaks-based company was founded by Westlake in 2020, reinforcing Westlake's commitment to building world-class biotech companies in the Los Angeles area. Recruiting local talent with expertise in neuroscience, pain, and drug discovery allowed Latigo to innovate and quickly advance to a clinical stage..

这家总部位于千橡园的公司由西湖于2020年成立，加强了西湖在洛杉矶地区建设世界一流生物技术公司的承诺。招募具有神经科学、疼痛和药物发现专业知识的当地人才，使拉蒂戈能够创新并迅速进入临床阶段。。

'It is particularly gratifying for me to participate in the evolution of Latigo over the past several years since its inception,' said Dr. Padhi. 'With a strong syndicate of investors and the significant capital we've raised, we are well positioned to build a company that provides new therapeutic options to patients with pain.

帕迪博士说：“在拉蒂戈成立以来的过去几年里，我特别高兴地参与到它的演变中。”凭借强大的投资者财团和我们筹集的大量资金，我们有能力建立一家为疼痛患者提供新治疗选择的公司。

Latigo's targets are identified by human genetics, grounded in human biology, and characterized using state-of-the-art human model systems. This combination increases our probability of success across the development continuum.'Latigo's lead program, LTG-001, is an oral, selective Nav1.8 inhibitor currently in a Phase 1 clinical trial in healthy volunteers and intended to treat acute and chronic pain.

拉蒂戈的目标由人类遗传学确定，以人类生物学为基础，并使用最先进的人类模型系统进行表征。这种组合增加了我们在整个发展过程中取得成功的可能性。”Latigo的主要项目LTG-001是一种口服选择性Nav1.8抑制剂，目前正在健康志愿者的1期临床试验中，旨在治疗急性和慢性疼痛。

LTG-001 has the potential to be best-in-class with a rapid onset, meaningful efficacy, and superior safety to standard of care with no central nervous system effects. In addition to LTG-001, the company has a suite of Nav1.8 inhibitors, enabling Latigo to address the broad potential of such a target in the clinic.Beyond Nav1.8, the company has a pipeline of novel, genetically identified targets with small molecule programs at the discovery stage.'Until recently, there was little innovation in pain therapeutics.

LTG-001有可能成为同类最佳，起效迅速，疗效有意义，安全性优于标准护理，无中枢神经系统影响。除LTG-001外，该公司还拥有一套Nav1.8抑制剂，使Latigo能够在临床上解决此类靶标的广泛潜力。除了Nav1.8之外，该公司还在发现阶段通过小分子程序拥有一系列新颖的基因识别目标。”直到最近，疼痛疗法几乎没有创新。

Current treatments have significant liabilities – opioids carry the risk of dependency, while NSAIDs can be poorly tolerated with long term use,' said Dr. Stagliano. 'Today, with a potentially best-in-class clinical-stage Nav1.8 inhibitor as our lead program, Latigo is fulfilling its vision of developing non-opioid therapies for patients suffering from acute and chronic pain where there is a significant high unmet need for new treatments.'About Latigo BiotherapeuticsLatigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privatel.

Stagliano博士说，目前的治疗方法有很大的责任——阿片类药物有依赖的风险，而非甾体抗炎药长期使用的耐受性很差如今，Latigo以一种潜在的一流临床阶段Nav1.8抑制剂作为我们的主导项目，正在实现其为患有急性和慢性疼痛的患者开发非阿片类药物治疗的愿景，这些患者对新治疗的需求尚未得到满足。”关于Latigo Biotherapeutics总部位于加利福尼亚州千橡树市的Latigo Biotherapeutics Inc.是一家私人公司。